Abstract:Despite significant investment into treatments for AD, little progress has been made in bringing new therapeutics to market. Recent failure of monoclonal antibodies targeting Ab plaques to slow disease progression in phase 3 clinical trials, suggests now more than ever it is imperative to identify early disease signatures before symptom onset whose modification may alter disease trajectory. Our collaborating lab recently identified early dysfunction in the transgenic tri‐synaptic hippocampal circuit using in vivo recordings during awake immobility in the TgF344‐AD rat model (doi: 10.1101/2021.05.10.443512). This dysfunction emerges between 6‐9 months, prior to when TgF344‐AD rat shows overt pathology (including Ab plaques, frank neuronal loss, and endogenous tau pathology) at 16 and 26 mo, but not at 6 mo (Towne, 2013). The molecular basis of this trisynpatic circuit dysfunction was explored using 10x Genomics’ v3 gene expression assay to perform snRNA‐seq on freshly dissected hippocampi from 6 mo male and female littermate pairs of Tg and Wt rats (n=16). ∼2000 cells/subject were collected, and cDNA libraries were sequenced (NovaSeq 600) to a depth of ∼120k reads/nuclei. Cell Ranger Pipeline demultiplexed and aligned reads to rat pre‐mRNA reference and generated gene count matrices. A final dataset of 33,079 high quality nuclei were clustered (Louvain graph‐based), and cell‐type specific marke used to determine identity. Identity was collapsed into broad neuronal and glial cell types for differential gene expression (DEG) across genotype (Hurdle Model). DEGs revealed profound alterations between genotype in cell types important in the trisynaptic circuit, including dentate granule cells (DGCs), and excitatory neurons (ExcNs). (FDR cutoff=0.05, 1111 (DGCs) and 1070 (ExcN’s) DEGs between genotypes). Pathway enrichment revealed dysregulation relevant to memory function: including decreased synaptogenesis, neurite branching, proliferation, and microtubule and cytoskeleton dynamics. DEG’s were enriched for neurological signs including epilepsy, seizures, hyperactivity, and dementia. Prior to development of overt pathology or memory deficits, TgF344‐AD rats display transcriptomic alterations in their excitatory neurons, suggestive of impaired ability to form new connections and susceptibility to aberrant, hyperactivity. Electrophysiological detection, followed by intervention targeting these early alterations in gene expression may prevent progression of disease to a symptomatic stage.

A Rat Model Established by Simulating Genetic-Environmental Interactions Recapitulates Human Alzheimer's Disease Pathology.

An App knock-in rat model for Alzheimer’s disease exhibiting Aβ and tau pathologies, neuronal death and cognitive impairments

Acrolein, an endogenous aldehyde induces Alzheimer's disease-like pathologies in mice: A new sporadic AD animal model

Praxiological,neurobiochemical and pathological characteristics of experimental animal model of Alzheimer's disease

Age‐ and sex‐dependent differences in cognitive decline in rat models of Alzheimer’s disease

Animal Models for Alzheimer’s Disease: a Focused Review of Transgenic Rodent Models and Behavioral Assessment Methods

Past Misconceptions and Future Prospects

Modeling Alzheimer’s Disease in Mouse without Mutant Protein Overexpression: Cooperative and Independent Effects of Aβ and Tau

Large-scale gene expression changes in APP/PSEN1 and GFAP mutation models exhibit high congruence with Alzheimer’s disease

Modeling sporadic Alzheimer's disease in mice by combining Apolipoprotein E4 risk gene with environmental risk factors

Data from single nuclei RNA‐sequencing reveals a prodromal gene network response in excitatory neurons of a humanized rat Alzheimer’s disease model

Memory deficiency, cerebral amyloid angiopathy, and amyloid-β plaques in APP+PS1 double transgenic rat model of Alzheimer’s disease

Insight into the emerging and common experimental in-vivo models of Alzheimer's disease

Animal Models of Alzheimer's Disease: Current Strategies and New Directions.

Robust neuroinflammation and perivascular pathology in rTg-DI rats, a novel model of microvascular cerebral amyloid angiopathy

Modeling Alzheimer'S Disease In Mouse Without Mutant Protein Overexpression: Cooperative And Independent Effects Of A Beta And Tau

Thy1-ApoE4/C/EBPβ double transgenic mice act as a sporadic model with Alzheimer's disease

Β-Amyloid Accumulation Enhances Microtubule Associated Protein Tau Pathology in an APPNL-G-F/MAPTP301S Mouse Model of Alzheimer’s Disease

APP mouse models for Alzheimer's disease preclinical studies

Advance of Sporadic Alzheimer's Disease Animal Models

Lack of Human-Like Extracellular Sortilin Neuropathology in Transgenic Alzheimer’s Disease Model Mice and Macaques